


PRODUCT INFORMATION



ABX-464

Item No. 39515

CAS Registry No.: 1258453-75-6
Formal Name: 8-chloro-N-[4-(trifluoromethoxy)phenyl]-2-quinolinamine
MF: C₁₆H₁₀ClF₃N₂O
FW: 338.7
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ABX-464 is supplied as a solid. A stock solution may be made by dissolving the ABX-464 in the solvent of choice, which should be purged with an inert gas. ABX-464 is soluble in acetonitrile and DMSO.

Description

ABX-465 is an HIV anti-replicative agent.¹ It associates with the human cap-binding complex, a complex that processes pre-mRNA, and induces aberrant splicing in HIV pre-mRNA expressed from host-integrated viral DNA. ABX-465 produces non-typical mRNA in primary peripheral blood mononuclear cells (PBMCs) from HIV-infected patients without disrupting normal cellular mRNA splicing when used at a concentration of 5 μM. ABX-465 increases the expression of the anti-inflammatory miR-124 in both uninfected and HIV-infected PBMCs at the same concentration. It reduces the replication of seven HIV-1 mutant strains by 71-99% in HIV-infected primary PBMCs.² *In vivo*, ABX-465 (20 mg/kg per day) reduces HIV RNA levels and losses of CD4⁺, CD8⁺, and CD4⁺/CD8⁺ T cells in isolated peritoneal cells, as well as limits the extent of viral rebound, in a humanized mouse model of HIV infection. It also prevents weight loss and decreased colon length, increases in colon lesion number and size, and the number of macrophage infiltrates into colon tissue in a mouse model of ulcerative colitis induced by dextran sodium sulfate (DSS; Item No. 23250) when administered at a dose of 50 mg/kg per day.³

References

1. Vautrin, A., Manchon, L., Garcel, A., *et al.* Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. *Sci. Rep.* **9**(1), 792 (2019).
2. Campos, N., Myburgh, R., Garcel, A., *et al.* Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis. *Retrovirology* **12**, 30 (2015).
3. Chebli, K., Papon, L., Paul, C., *et al.* The anti-HIV candidate Abx464 dampens intestinal inflammation by triggering IL-22 production in activated macrophages. *Sci. Rep.* **7**(1), 4860 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/26/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM